Lower-dose chemotherapy for frail adults with leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a personalized, lower-dose chemotherapy plan can help adults with acute lymphoblastic leukemia (ALL) who are frail or have other health problems. It aims to improve survival by adjusting the dose to what each person can handle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute lymphoblastic leukemia (ALL) by your doctor.
- You are 18 years or older.
- You are considered 'frail' — meaning your daily activities are limited (ECOG score above 1) or your ability to do normal tasks is lower (Karnofsky score below 80%).
- You have other health conditions like diabetes, high blood pressure, blood clots, or prior side effects from standard chemo that make full-dose treatment difficult.
- You have not had a treatment before that was already a low-dose plan for your health conditions.
- You are not pregnant, and you do not have leukemia that has spread to the brain requiring radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This study tests a combination of a lower-dose chemotherapy and a short course of an immunotherapy drug called blinatumomab, before a stem cell transplant, to see if it helps improve outcomes for adults with certain types of ALL.
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
Hear when a new Acute Lymphobkastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.